Pharmacy Compounding Accreditation Consulting — PCAB, USP 795, 797 & 800 | Integral Healthcare Solutions

Last updated: April 2026

IHS provides specialized accreditation consulting for compounding pharmacies navigating PCAB accreditation and the revised USP Chapters 795, 797, and 800 — all three of which achieved final enforceable status on November 1, 2023. We cover the full compliance lifecycle: gap assessment, SOP development, mock survey, on-site inspection support, and post-survey remediation. Thomas G. Goddard, JD, PhD leads every engagement personally.

Schedule a PCAB Gap Assessment with IHS

What Is PCAB Accreditation?

PCAB (Pharmacy Compounding Accreditation Board) is the premier accreditation credential for compounding pharmacies in the United States. Administered as a service of ACHC (Accreditation Commission for Health Care) since PCAB's founding by a coalition of eight national pharmacy organizations in 2007, PCAB accreditation signals that a compounding pharmacy has demonstrated rigorous adherence to USP Chapter 795, 797, and 800 requirements through independent third-party review.

The U.S. compounding pharmacy market is valued at $6.98 billion in 2025 and projected to reach $12.79 billion by 2035 at a 6.24% CAGR (Precedence Research). Yet fewer than 1% of all U.S. pharmacies currently hold PCAB accreditation (ACHC PCAB) — and 21% of dedicated compounding-volume pharmacies hold it (APC 2023–2024 Demographic Survey). An additional 16% of unaccredited compounding pharmacies plan to pursue PCAB accreditation within five years.

The American Medical Association formally recommends that physicians use exclusively PCAB-accredited compounding pharmacies — making accreditation an increasingly essential prerequisite for physician referral network access. Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure.

Who Needs PCAB Accreditation?

Six categories of organizations pursue PCAB accreditation or USP compliance consulting:

Dedicated 503A compounding pharmacies — independent, single-location, pursuing PCAB for state licensure, physician referral access, and payer credentialing
503B outsourcing facilities — 83 active FDA-registered facilities as of March 2026 (FDA); highest consulting demand and complexity
Hybrid pharmacies — dispensing both compounded and commercial drugs; must segregate compounding operations to PCAB standards
Hospital pharmacy departments — compounding sterile preparations under USP 797 for inpatient use
Oncology pharmacies — handling hazardous drugs under USP 800
Specialty pharmacies — adding compounding capabilities to existing accreditation structures (URAC, ACHC, NABP)

USP Chapters 795, 797, and 800: What Each Requires

All three USP chapters simultaneously achieved final enforceable status on November 1, 2023 — the most significant regulatory event in compounding pharmacy history since the Drug Quality and Security Act of 2013. PCAB accreditation is built around demonstrating compliance with all three chapters as an integrated framework.

USP Chapter 795: Non-Sterile Compounding

USP 795 governs non-sterile preparations — creams, ointments, capsules, oral liquids, and similar dosage forms. The November 2023 final version introduced a water activity metric and stricter beyond-use date (BUD) defaults. Master Formulation Records must now document stability data meeting the new water activity standards. Organizations that relied on legacy BUD tables from pre-2023 guidance must review and update every affected formulation.

USP Chapter 797: Sterile Compounding

USP 797 is the most complex and most surveyed of the three chapters. The 2023 final version replaced the former risk-level framework (low/medium/high) with a Category 1/2/3 BUD continuum tied to environmental control level. Key new requirements include:

Formal Designated Person (DP) designation with documented responsibilities
Semi-annual gloved fingertip and thumb sampling for all sterile compounding personnel
Media fill testing documentation before personnel may manipulate patient drugs
Environmental monitoring at frequencies tied to Category classification
Shipping system validation — scientifically validated packaging for all product transit

USP Chapter 800: Hazardous Drug Handling

USP 800 governs the receipt, storage, compounding, dispensing, and disposal of hazardous drugs. It applies to any pharmacy that handles drugs on the NIOSH hazardous drug list — including many oncology, hormonal, and antiviral compounds commonly compounded for specialty uses. Key requirements include containment ventilated enclosures, specific gowning protocols, negative pressure areas, and deactivation/decontamination procedures.

The 503A vs. 503B Distinction

The Drug Quality and Security Act (DQSA, 2013) bifurcated the compounding industry into two tracks. 503A pharmacies compound patient-specific prescriptions and are regulated primarily by state boards of pharmacy under USP standards. 503B outsourcing facilities register with FDA and compound for office stock without patient-specific prescriptions, subject to current Good Manufacturing Practice (cGMP) requirements. IHS serves both tracks — with distinct consulting approaches for each regulatory framework.

The Current Regulatory Environment: Why Now Matters

Several converging forces are creating urgent compliance demand in 2025 and 2026:

State Board Enforcement Wave

Each state is reaching its own USP enforcement deadline on a rolling basis. Kentucky began active enforcement of revised USP 795/797/800 on January 1, 2026. Ohio extended its grace period through February 28, 2027 — creating a prolonged consulting demand window in the Ohio market. Every state reaching its statutory enforcement deadline generates a fresh wave of compliance consulting engagements. Organizations in pre-enforcement states should not wait for their deadline to begin preparation.

GLP-1 Regulatory Transition

The FDA's enforcement discretion for 503A pharmacies compounding semaglutide products terminated in April 2025, and for 503B facilities in May 2025. Pharmacies that built operations around GLP-1 compounding must now either exit this segment or navigate the formal prior authorization pathway. This transition requires specialized regulatory counsel — and represents a major compliance consulting engagement category in 2025.

Nonresident Licensure Requirements

Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure. California charges an $8,500 nonresident sterile compounding pharmacy license fee (California Board of Pharmacy). For multi-state operations, PCAB accreditation is not optional — it is a state licensure prerequisite in key markets.

Private Equity Due Diligence

Private equity firms assign 6x–10x EBITDA valuations to compounding operators with clean inspection histories. For organizations approaching M&A events, PCAB accreditation is a valuation driver — not an operating overhead. The FDA's $20,726 annual establishment fee for 503B facilities (FDA FY2026) underscores the investment scale these organizations are protecting with compliance infrastructure.

The PCAB Accreditation Process: Phase by Phase

PCAB accreditation typically takes 7 to 8 months from initial consulting engagement, assuming baseline state inspections are complete. A full de novo build from a non-compliant state requires 12 to 18 months. Here is how IHS structures the engagement.

Comprehensive Gap Assessment (Weeks 1–2)

IHS conducts an exhaustive review of your current clinical practices, physical environment, and documentation history against the finalized USP 795, 797, and 800 standards. Every liability is identified. The gap report is the foundation for the entire engagement timeline and internal resource plan.

Policy and Procedure (SOP) Development (Weeks 3–14)

The most time-intensive phase. IHS distributes customized policy chapters over 12 weeks, allowing pharmacy staff to digest, implement, and demonstrate compliance with one complex chapter before moving to the next. This sequenced approach prevents the documentation overwhelm that causes most pharmacy PCAB preparations to stall. Key SOP domains include: cleanroom maintenance, environmental excursions, garbing sequences, hand hygiene, equipment calibration, shipping validation, Designated Person responsibilities, and hazardous drug handling.

Mock Survey and Remediation (Weeks 15–18)

IHS conducts a rigorous simulated audit including real-time observation of aseptic techniques, environmental monitoring log scrutiny, and staff competency testing. Gloved fingertip sampling and media fill documentation are verified against USP 797 requirements. An immediate remediation plan is developed for every identified gap.

Application and Document Submission (Week 19)

Formal application submitted to ACHC with all required legal documentation and the comprehensive Preliminary Evidence Report. IHS manages the submission process and anticipates common documentation deficiencies before they trigger ACHC requests for information.

Formal On-Site Survey (Months 5–8)

ACHC's formal binding evaluation — which can be unannounced. IHS prepares your team for every element of surveyor assessment: aseptic technique observation, personnel record review, equipment calibration log audit, and environmental monitoring documentation. Organizations that complete mock survey with IHS arrive at formal survey without surprises.

Internal Staffing Requirements

A critical mistake: assuming external consulting eliminates internal staff commitment. PCAB preparation requires massive dedicated internal resources regardless of consultant involvement.

Designated Person — 1.0 FTE for quality program oversight (legally required under new USP frameworks)
Pharmacist-in-Charge — 0.5 FTE for documentation oversight during preparation
All compounding staff — participation in competency demonstrations, media fill testing, and gloved fingertip sampling

PCAB Accreditation Cost and Timeline

PCAB/ACHC does not publish a universal rate card. Organizations request customized quotes through ACHC's Customer Central portal. The Alliance for Pharmacy Compounding (APC) members receive a $1,000 discount off base PCAB accreditation fees.

ACHC/PCAB Direct Fees

Base PCAB accreditation fee: Upper thousands to low tens of thousands (historically $1,250–$5,000 under PCAB's original pricing; current fees are higher under ACHC partnership)
APC member discount: $1,000 off base fee
Accreditation cycle: 36 months; renewal must begin 9 months before expiration
Annual maintenance fee: None — costs consolidated into triennial survey

State Licensure Fees (Select States)

California nonresident sterile compounding pharmacy license: $8,500 (California Board of Pharmacy)
503B FDA annual establishment fee (FY2026, non-small business): $20,726 (FDA)

IHS Consulting Fees

Operational audit and full mock survey: $5,000–$10,000
Regulatory compliance remediation: $3,000–$7,000
Full PCAB preparation package: approximately $4,000 plus ~$1,000 for customized SOP manuals
Ad-hoc hourly consulting: $75–$125/hour (generalist); $150–$250/hour (experienced); $300+/hour (former FDA inspectors or cleanroom engineering specialists)
503B cGMP engagements: Scope and cost are substantially higher — contact IHS for a custom assessment

Most Common PCAB Inspection Deficiencies and How to Avoid Them

The following deficiencies are the most frequently cited in PCAB surveys, based on ACHC's 2024 Surveyor Quality Review. IHS builds prevention protocols for each into every engagement.

Equipment Calibration and Maintenance — 48% Citation Rate (Most Cited in 2024)

Failure to adequately clean, maintain, or keep rigorous calibration logs for sensitive compounding equipment. IHS implements comprehensive equipment log templates with electronic alert triggers for calibration due dates.

Safe Storage, Labeling, and Handling — 41% Citation Rate

Failure to continuously monitor, maintain, and document appropriate environmental metrics — temperature, humidity, pressure differentials — within the pharmacy. IHS establishes continuous monitoring systems with documented excursion response protocols.

Shipping System Validation — 37% Citation Rate

Pharmacies failing to use scientifically validated shipping materials guaranteeing appropriate temperature and sanitation during transit. IHS builds shipping validation packages that satisfy USP and PCAB requirements for every product category shipped.

Designated Person Designation — 31% Citation Rate

Failure to formally appoint, document, and define the responsibilities of a Designated Person as required under the new USP frameworks. IHS drafts the formal DP designation documentation and role charter required by both USP 797 and ACHC standards.

Personnel Training and Competency — Over 25% Citation Rate

Failure to maintain continuous documented training logs for staff engaged in complex compounding procedures. IHS builds the full competency assessment framework: initial training, semi-annual reassessment, and direct observation documentation for each procedure type.

Gloved Fingertip and Thumb Sampling Gaps

Total absence or lapsed documentation of required initial and ongoing semi-annual gloved fingertip sampling. This is a non-negotiable USP 797 requirement — and one of the first things PCAB surveyors check. IHS establishes the sampling schedule, documentation format, and remediation protocol for positive results.

Media Fill Testing Gaps

Missing documentation that personnel passed mandatory aseptic media fill challenges before manipulating actual patient drugs. IHS coordinates media fill testing events and builds the records package required for ongoing PCAB compliance.

Why Choose IHS for PCAB Accreditation and USP Compliance Consulting

Thomas G. Goddard, JD, PhD, leads IHS's pharmacy accreditation practice with 25+ years of consulting expertise across PCAB, URAC specialty pharmacy, and NABP programs. Here is what differentiates IHS from other compounding pharmacy consultants.

Integrated coverage: Unlike engineering-only firms (cleanroom specialists) or education-only platforms (e-learning providers), IHS provides integrated consulting covering the full compliance lifecycle — gap assessment, SOP development, mock survey, inspection defense, and post-survey remediation.
Regulatory interplay expertise: IHS understands the interplay between PCAB, state board enforcement timelines, and FDA regulatory posture. This is critical for multi-state operations and 503B facilities navigating dual state/federal oversight.
State enforcement timeline knowledge: Kentucky enforcing January 2026. Ohio enforcing February 2027. IHS provides state-specific transition planning that accounts for your state's actual enforcement calendar — not a generic national timeline.
503A and 503B expertise: IHS serves both regulatory tracks. For 503A pharmacies, the focus is PCAB accreditation and state board compliance. For 503B facilities, IHS provides cGMP consulting, FDA inspection preparation, and Form 483 response support.
GLP-1 transition counsel: IHS helps 503A pharmacies navigate the post-enforcement-discretion regulatory landscape for semaglutide and tirzepatide — one of the highest-demand consulting categories in 2025.
Principal-led engagement: Dr. Goddard leads every IHS engagement. You work directly with the firm's principal, not a junior associate.

Frequently Asked Questions

See our complete PCAB Accreditation and USP Compliance FAQ for 15+ detailed answers.

What changed with the revised USP Chapter 797 effective November 2023?

The 2023 final version replaced the old risk-level framework (low/medium/high BUD) with a Category 1/2/3 BUD continuum tied to environmental control level. New requirements include: formal Designated Person designation, semi-annual gloved fingertip sampling, media fill testing documentation, category-specific environmental monitoring frequencies, and shipping system validation. Most compounding pharmacies needed substantial SOP and procedure updates to achieve compliance.

Does PCAB accreditation satisfy state board of pharmacy USP compliance requirements?

PCAB accreditation demonstrates rigorous compliance with USP 795, 797, and 800 through independent third-party verification — which is the same standard most state boards are enforcing. However, state board requirements and PCAB standards are not legally identical. IHS helps organizations understand their specific state board requirements and how PCAB accreditation status affects their state compliance posture.

What is the difference between PCAB and NABP VPP?

PCAB focuses specifically on compounding pharmacy quality and is administered through ACHC. NABP's Verified Pharmacy Program (VPP) is a broader pharmacy accreditation covering dispensing, operations, and patient safety. For dedicated compounding pharmacies, PCAB is the more directly relevant credential. See our full PCAB vs. NABP VPP comparison.

Which states require PCAB accreditation for nonresident compounding pharmacy licensure?

Washington and Ohio currently require verifiable PCAB accreditation as a condition of nonresident compounding pharmacy licensure. Additional states are tracking these requirements as enforcement of USP 795/797/800 matures across jurisdictions. IHS monitors state board developments and provides current state-specific guidance in every engagement.

Ready to Start Your PCAB Accreditation Preparation?

Schedule a no-obligation gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your current compliance posture against USP 795, 797, and 800 requirements and give you a clear phased roadmap to PCAB accreditation.

Schedule Your PCAB Gap Assessment